Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — AbbVie CEO Richard Gonzalez is in for a congressional tongue-lashing of outsized proportion. And it couldn’t come at a worse time.

Just two years ago, AbbVie seemed on the verge of serious financial trouble. Now, investors are openly proclaiming the pharma giant as one of their favorite stock picks. AbbVie exceeded its projected earnings last month, even while other pharma giants like Merck fell short. Its stock is trading near a 52-week high.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.